• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer

    5/18/23 8:00:00 AM ET
    $ALLO
    $AMGN
    $MRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALLO alert in real time by email

    Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer

    • Arun Balakumaran M.D., Ph.D, appointed Chief Medical Officer of Replay to support the Company's genomic medicine and engineered NK cell therapy pipeline
    • Former Chief Medical Officer of allogeneic CAR-T cell company Allogene Therapeutics and seasoned industry immuno-oncology, and cell and gene therapy expert
    • Dr. Balakumaran also appointed CMO of Syena, Replay's engineered NK cell therapy product company pioneering first-in-class engineered T-cell Receptor Natural Killer cell (TCR-NK) therapy

    San Diego, California and London, UK, May 18, 2023 – Replay, a genome writing company reprogramming biology by writing and delivering big DNA, today announced the appointment of Arun Balakumaran, M.D., Ph.D., as Chief Medical Officer (CMO), effective 22 May.

    An expert in immuno-oncology and cell and gene therapy, Dr. Balakumaran brings more than 15 years of clinical development experience at leading biotechnology and pharmaceutical companies, including Merck and Amgen, to the Company. At Replay, Dr. Balakumaran will support the clinical development of Replay's differentiated portfolio of next-generation genomic medicines and technology platforms, including its first-in-class engineered TCR-NK cell therapy programs that are anticipated to enter the clinic later this year.

    Dr. Balakumaran joins Replay from Allogene Therapeutics (NASDAQ:ALLO), where he served as CMO and Senior Vice president, overseeing the Company's clinical development strategy across multiple allogeneic cell therapy programs. Prior to that, he held roles of increasing seniority at Merck (NASDAQ:MRK), where he was the Product Development Lead for Hematological Malignancies and led the activities resulting in breakthrough designations and the eventual approval of Pembrolizumab® in lymphoma. Prior to that he was Clinical Research Medical Director at Amgen (NASDAQ:AMGN), and Medical Lead in Oncology.

    Dr. Balakumaran began his career at the National Institutes of Health (NIH), where he was Medical Lead for the Bone Marrow Stromal Cells (MSC) Transplant Center. He is a board-certified hematologist and medical oncologist and holds a Master's degree in healthcare management from Harvard University. Dr. Balakumaran also serves on the Board of Onco Filtration Inc. and the Scientific Advisory Board of SDS Optic.

    Dr. Balakumaran will, additionally, join Replay's engineered TCR-NK cell therapy product company Syena as CMO, where he will support the clinical development of its first-in-class and first-in-human engineered TCR-NK cell therapy clinical programs in both hematological malignancies and solid tumors. Syena was co-founded by Professor Katy Rezvani, M.D., Ph.D., and is developing a scalable, off-the-shelf, cord blood-derived engineered TCR-NK platform, which was licensed exclusively from The University of Texas MD Anderson Cancer Center, in February 2023.

    Adrian Woolfson, Executive Chairman, President, and Co-Founder of Replay, commented: "Arun's extensive expertise across cell and gene therapy, and immuno-oncology, will be invaluable for Replay and its product companies, including our first-in-class engineered TCR-NK cell therapy company, Syena. He will be joining a rapidly expanding team of world-class industry experts, academics, and entrepreneurs at Replay, where we are focused on delivering new therapeutic options for some of the key global medical challenges addressable using genomic medicine and engineered cell therapies. We are delighted to welcome him into our team."

    Lachlan MacKinnon, CEO and Co-Founder of Replay, added, "We have watched Arun's progress at Allogene Therapeutics where he has been instrumental in advancing their allogeneic cell therapy programs into the clinic. His knowledge and experience will be of critical importance to the Company as we progress our genomic medicine pipeline, including the first-in-class TCR-NKs that we are developing within our engineered TCR-NK cell therapy product company, Syena."

    "Replay has the potential to transform the future of genomic medicine through its suite of genomic medicine platform technologies, engineered cell therapies, and innovative approach to corporate structure and product development," said Dr. Arun Balakumaran, Chief Medical Officer of Replay. "The engineered TCR-NK platform that is being developed in Syena in particular, provides the promise of a highly scalable and off-the-shelf cell therapy with the potential to evade the primary mechanism of acquired resistance in existing cell therapies, through their innate anti-tumor activity. I look forward to working with the Replay executive team, Katy Rezvani at MD Anderson, and the Syena team to progress engineered TCR-NKs and the Company's other programs and technologies including HSV-based gene therapy, into the clinic for the benefit of patients with high unmet medical needs."

    Ends

    About Replay

    Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and delivering big DNA. The Company has assembled a toolkit of disruptive platform technologies – including a high payload capacity HSV platform, a hypoimmunogenic cell therapy platform, and a genome writing platform – to address the scientific challenges currently limiting clinical progress and preventing genomic medicine from realizing its full potential. The Company's hub-and-spoke business model separates technology development within Replay from therapeutic development in product companies that leverage its technology platforms. For example, the Company recently incorporated a first-in-class engineered TCR-NK cell therapy product company developed by Professor Katy Rezvani at the MD Anderson Cancer Center. Replay's synHSV™ technology, a high payload capacity HSV vector capable of delivering up to 30 times the payload of AAV, is utilized by Replay's four gene therapy product companies, bringing big DNA treatments to diseases affecting the skin, eye, brain, and muscle. Replay is led by a world-class team of academics, entrepreneurs, and industry experts.

    The Company raised $55 million in seed financing in July 2022 and is supported by an international syndicate of investors including: KKR, OMX Ventures, ARTIS Ventures, and Lansdowne Partners.

    Replay is headquartered in San Diego, California, and London, UK. For further information please visit www.replay.bio and follow us on LinkedIn and Twitter. 

    Contacts:

    Replay

    Dr Adrian Woolfson / Lachlan MacKinnon

    [email protected]

    Consilium Strategic Communications – Media relations

    Amber Fennell / David Daley / Melissa Gardiner

    [email protected]



    Primary Logo

    Get the next $ALLO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLO
    $AMGN
    $MRK

    CompanyDatePrice TargetRatingAnalyst
    Merck & Company Inc.
    $MRK
    10/13/2025$95.00Neutral
    Citigroup
    Allogene Therapeutics Inc.
    $ALLO
    10/10/2025Neutral → Underweight
    Analyst
    Merck & Company Inc.
    $MRK
    9/17/2025$90.00Buy → Hold
    Berenberg
    Amgen Inc.
    $AMGN
    9/3/2025Mkt Perform
    Raymond James
    Amgen Inc.
    $AMGN
    5/20/2025$288.00Neutral
    Guggenheim
    Merck & Company Inc.
    $MRK
    5/14/2025$84.00Buy → Neutral
    Citigroup
    Allogene Therapeutics Inc.
    $ALLO
    5/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    Merck & Company Inc.
    $MRK
    4/22/2025$85.00Neutral
    Cantor Fitzgerald
    More analyst ratings

    $ALLO
    $AMGN
    $MRK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    11/21/24 12:43:07 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for PAVBLU issued to AMGEN INC

    Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:

    8/26/24 5:53:38 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    8/21/24 12:12:47 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLO
    $AMGN
    $MRK
    SEC Filings

    View All

    SEC Form 144 filed by Allogene Therapeutics Inc.

    144 - Allogene Therapeutics, Inc. (0001737287) (Subject)

    10/21/25 8:52:12 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Allogene Therapeutics Inc.

    8-K - Allogene Therapeutics, Inc. (0001737287) (Filer)

    10/10/25 5:31:11 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Merck & Company Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Merck & Co., Inc. (0000310158) (Filer)

    9/9/25 4:33:09 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLO
    $AMGN
    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Seidman Christine E

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    10/2/25 9:31:14 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Glocer Thomas H

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    10/2/25 9:29:34 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Coe Mary Ellen

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    10/2/25 9:28:01 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLO
    $AMGN
    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults

    Findings presented at IDWeek 2025 underscore the importance of considering serotypes that disproportionately impact adults in the U.S. and show greater resistance to commonly prescribed antibiotics Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of findings from a systematic literature review of studies on the epidemiology and antimicrobial resistance (AMR) of pneumococcal serotypes covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. adults. The evaluation examined 15 studies published between 2015 and 2025 to assess the serotype-specific burden of pneumococcal disease (PD) associated with serotypes covered by C

    10/21/25 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)

    Five-year exploratory follow-up analysis of KEYNOTE-671 continued to show clinically meaningful improvements in overall survival and event-free survival with KEYTRUDA plus chemotherapy before surgery, and then continued as a single agent after surgery Eight and 10-year findings from analyses of KEYNOTE-001, KEYNOTE-010, KEYNOTE-024 and KEYNOTE-042 show that KEYTRUDA monotherapy continued to improve survival for certain patients with locally advanced or metastatic NSCLC, supporting its role as a standard of care Results presented at the European Society for Medical Oncology (ESMO) Congress 2025 Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced new

    10/20/25 8:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia

    The expansion underscores Merck's commitment to invest more than $70 billion in U.S. research, development and capital projects Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today the start of construction for a $3 billion, 400,000-square-foot pharmaceutical manufacturing facility at its Elkton, Virginia, site. Merck's investment in the Center of Excellence for Pharmaceutical Manufacturing is part of a more than $70 billion investment beginning in 2025 to expand domestic manufacturing and research and development — not including any future business development transactions in R&D — to drive its long-term growth and strengthen the status of the U.S. as

    10/20/25 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLO
    $AMGN
    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup resumed coverage on Merck with a new price target

    Citigroup resumed coverage of Merck with a rating of Neutral and set a new price target of $95.00

    10/13/25 8:54:29 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allogene downgraded by Analyst

    Analyst downgraded Allogene from Neutral to Underweight

    10/10/25 8:22:32 AM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Merck downgraded by Berenberg with a new price target

    Berenberg downgraded Merck from Buy to Hold and set a new price target of $90.00

    9/17/25 7:56:07 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLO
    $AMGN
    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thulin Inge G bought $250,000 worth of shares (2,833 units at $88.25), increasing direct ownership by 2,833% to 2,933 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:09:51 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Douglas M Jr bought $1,327,500 worth of shares (15,000 units at $88.50), increasing direct ownership by 1,500% to 16,000 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:04:52 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belldegrun Arie was granted 344,828 shares and bought $4,999,997 worth of shares (1,724,137 units at $2.90) (SEC Form 4)

    4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

    5/20/24 9:33:32 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLO
    $AMGN
    $MRK
    Financials

    Live finance-specific insights

    View All

    FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

    Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in adult and pediatric patients aged 12 years and older. TEZSPIRE is the first and only biologic approved for CRSwNP that targets thymic stromal lymphopoietin (TSLP). CRSwNP affects up to approximately 320 million people worldwide and is a complex epithelial-driven inflammatory condi

    10/17/25 4:00:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.

    Eligible Patients Can Access Repatha at Nearly 60% Discount From the List Price  THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha® (evolucumab). This follows landmark results demonstrating Repatha significantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke in the VESALIUS-CV Phase 3 trial. In support of the Trump Administration's efforts to lower drug prices for Americans, Repatha will be available through AmgenNow at a monthly price of $239, nearly 60% lower than the current U.S. list price. The

    10/6/25 9:00:00 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS

    Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Compared with Standard Therapy Alone Repatha is Now the First and Only PCSK9 Inhibitor to Demonstrate Significant Reduction of Cardiovascular Events as Both Primary and Secondary Prevention THOUSAND OAKS, Calif., Oct. 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints demonstrating that Repatha® (evolocumab) significantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke. The landmark Phase 3 VESALIUS-CV trial enr

    10/2/25 9:00:00 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLO
    $AMGN
    $MRK
    Leadership Updates

    Live Leadership Updates

    View All

    REPAY Appoints New Chief Financial Officer

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    Real Estate
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer

    NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer Ingelheim senior leader joins NodThera Leadership TeamWill spearhead clinical advancement of the company's innovative NLRP3 inflammasome inhibitor portfolioBrings deep clinical leadership in obesity and cardiometabolic diseases, with a proven track record guiding programs from early-stage development through Phase 3 and regulatory approval Philadelphia, PA, July 21, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appoi

    7/21/25 7:00:00 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GeminiBio Appoints Mike Stella to Board

    Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

    2/18/25 9:00:00 AM ET
    $AMGN
    $GSK
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    $ALLO
    $AMGN
    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Allogene Therapeutics Inc.

    SC 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)

    11/12/24 1:26:25 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Allogene Therapeutics Inc.

    SC 13G - Allogene Therapeutics, Inc. (0001737287) (Subject)

    11/4/24 10:57:36 AM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Allogene Therapeutics Inc. (Amendment)

    SC 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)

    2/14/24 4:36:10 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care